Arming the Immune System to Kill Cancer

Our “off the shelf” stem cells deliver a viral payload that first kills cancer cells locally, and then supercharges the immune system to fight metastatic disease.

A blue gloved hand holding a prescription bottle.

We are developing a new generation of targeted immunotherapies that  attack solid tumors, and then teach the immune system to hunt down cancer cells elsewhere in the body.

A person in blue gloves is filling a container with liquid.

Where does the “Calidi” name come from?

The Calidi name is derived from the spanish “caliente” meaning heat, which signifies that Calidi’s cancer treatment transforms immunologically “cold” tumors, which the immune system is unaware of,  becoming “hot” following Calidi’s treatment. The immune system is thus engaged, and attacks the primary tumor and also distant metastases.

Discover the latest from our facility

In the Pipeline: Next-Generation Therapies

Explore Calidi Biotherapeutics' robust and evolving lineup of innovative immunotherapies, each designed with precision and a vision for a healthier future.

A person in a lab coat working on a machine.

Meet the Visionaries Behind Calidi

Get to know the dedicated team at Calidi Biotherapeutics. A blend of experts and innovators, each member plays a pivotal role in our mission to redefine cancer treatment.

A man and woman in lab coats looking at something.

Calidi Newsroom:
Stay Updated

Dive into the latest updates, research findings, and announcements from Calidi Biotherapeutics. Stay informed about our strides in the world of immunotherapy.

A close up of a cell in the air.

Latest News

Press Release

Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference

February 12, 2024
Discover More
Discover More
Press Release

Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board. These oncology experts are among the country’s preeminent leaders in cancer biology and clinical care and join the company’s existing advisors who hail from top cancer research institutions and facilities collaborating with Calidi in the development of its novel immunotherapies targeting high-grade gliomas and solid tumors.

January 8, 2024
Discover More
Discover More
Press Release

Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced three presentations on Calidi’s NeuroNova (NNV) and SuperNova (SNV) allogeneic stem cell-based virotherapy platforms at the upcoming 8th Oncolytic Virotherapy Summit to be held December 12-14, 2023 in Boston, Mass.

December 13, 2023
Discover More
Discover More

A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.

Learn more